KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (ONC) EBITDA Margin: 2015-2025

Historic EBITDA Margin for BeOne Medicines (ONC) over the last 10 years, with Sep 2025 value amounting to 11.55%.

  • BeOne Medicines' EBITDA Margin rose 2356.00% to 11.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.67%, marking a year-over-year increase of 2998.00%. This contributed to the annual value of -14.91% for FY2024, which is 3421.00% up from last year.
  • As of Q3 2025, BeOne Medicines' EBITDA Margin stood at 11.55%, which was up 72.85% from 6.68% recorded in Q2 2025.
  • BeOne Medicines' EBITDA Margin's 5-year high stood at 89.06% during Q4 2021, with a 5-year trough of -316.58% in Q2 2021.
  • Its 3-year average for EBITDA Margin is -23.66%, with a median of -12.01% in 2024.
  • In the last 5 years, BeOne Medicines' EBITDA Margin soared by 72,953bps in 2021 and then plummeted by 21,235bps in 2022.
  • Quarterly analysis of 5 years shows BeOne Medicines' EBITDA Margin stood at 89.06% in 2021, then crashed by 21,235bps to -123.29% in 2022, then skyrocketed by 6,279bps to -60.50% in 2023, then soared by 5,345bps to -7.04% in 2024, then spiked by 2,356bps to 11.55% in 2025.
  • Its EBITDA Margin stands at 11.55% for Q3 2025, versus 6.68% for Q2 2025 and 0.99% for Q1 2025.